In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)

Piérard, D.; Stone, G. G.

doi:10.1186/s12879-021-06153-0

Table 2 Antimicrobial activity against resistant respiratory Enterobacterales isolates by subset (ATLAS 2016–2018)

From: In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)

Organism	Antimicrobial	MIC (mg/L)		%S	%I	%R
Organism	Antimicrobial	MIC₉₀	Range	%S	%I	%R
Enterobacterales, ESBL-positive (n = 1963)	Amoxicillin-clavulanate	≥64	1–≥64	14.5	N/A	85.5
	Piperacillin-tazobactam	≥256	≤0.25–≥256	40.4	12.5	47.1
	Aztreonam	≥256	0.06–≥256	0.7	4.2	95.1
	Ceftazidime	≥256	0.25–≥256	2.6	8.2	89.2
	Ceftazidime-avibactam	2	≤0.015–≥256	93.6	N/A	6.4
	Cefepime	≥64	≤0.12–≥64	2.9	7.4	89.8
	Imipenem	≥16	≤0.03–≥16	82.7	4.0	13.3
	Meropenem	16	0.015–≥32	84.1	3.3	12.6
	Levofloxacin	≥16	≤0.03–≥16	18.3	12.0	69.7
	Colistin (n = 1931)^a	1	≤0.06–≥16	94.6	N/A	5.4
	Amikacin	32	≤0.25–≥128	82.5	N/A	17.5
	Tigecycline^b	2	≤0.015–≥16	98.8	0.0	1.2
Enterobacterales, ESBL/carbapenemase- positive (n = 351)	Amoxicillin-clavulanate	≥64	1–≥64	0.6	N/A	99.4
	Piperacillin-tazobactam	≥256	0.25–≥256	1.7	0.3	98.0
	Aztreonam	≥256	0.12–≥256	1.1	2.0	96.9
	Ceftazidime	≥256	0.5–≥256	1.4	1.7	96.9
	Ceftazidime-avibactam	≥256	0.03–≥256	64.7	N/A	35.3
	Cefepime	≥64	≤0.12–≥64	1.1	2.6	96.3
	Imipenem	≥16	0.25–≥16	16.2	12.0	71.8
	Meropenem	≥32	0.03–≥32	18.8	13.7	67.5
	Levofloxacin	≥16	0.06–≥16	6.0	4.8	89.2
	Colistin (n = 346)^a	≥16	≤0.06–≥16	79.2	N/A	20.8
	Amikacin	≥128	0.5–≥128	58.1	N/A	41.9
	Tigecycline^b	2	0.06–8	92.9	0.0	7.1
Enterobacterales, carbapenemase positive/ MBL-negative (n = 362)	Amoxicillin-clavulanate	≥64	1–≥64	0.6	N/A	99.4
	Piperacillin-tazobactam	≥256	0.25–≥256	1.1	0.6	98.3
	Aztreonam	≥256	0.06–≥256	7.5	1.1	91.4
	Ceftazidime	≥256	0.25–≥256	7.5	3.3	89.2
	Ceftazidime-avibactam	4	≤0.015–≥256	98.9	N/A	1.1
	Cefepime	≥64	≤0.12–≥64	6.1	5.8	88.1
	Imipenem	≥16	0.25–≥16	19.3	14.6	66.0
	Meropenem	≥32	0.03–≥32	21.8	19.3	58.8
	Levofloxacin	≥16	0.06–≥16	7.2	5.2	87.6
	Colistin (n = 359)^a	≥16	≤0.06–≥16	74.1	N/A	25.9
	Amikacin	64	0.5–≥128	59.1	N/A	40.9
	Tigecycline^b	2	0.06–8	100	0.0	0.0
Enterobacterales, MBL-positive (n = 157)^c	Amoxicillin-clavulanate	≥64	32–≥64	0.0	N/A	100
	Piperacillin-tazobactam	≥256	2–≥256	3.8	0.0	96.2
	Aztreonam	≥256	≤0.015–≥256	10.8	3.8	85.4
	Ceftazidime	≥256	32–≥256	0.0	0.0	100
	Ceftazidime-avibactam	≥256	16–≥256	0.0	N/A	100
	Cefepime	≥64	4–≥64	0.0	1.3	98.7
	Imipenem	≥16	1–≥16	7.0	8.3	84.7
	Meropenem	≥32	0.25–≥32	10.8	15.9	73.2
	Levofloxacin	≥16	0.06–≥16	10.2	3.2	86.6
	Colistin (n = 146)^a	4	≤0.06–≥16	89.0	N/A	11.0
	Amikacin	≥128	0.5–≥128	42.7	N/A	57.3
	Tigecycline^b	2	0.12–8	90.0	0.0	10.0

MIC minimum inhibitory concentration; MIC₉₀ MIC required to inhibit the growth of 90% of isolates; %S percent susceptible, standard dosing regimen; %I percent susceptible, increased exposure; %R percent resistant; N/A not applicable; ESBL extended-spectrum β-lactamase; MBL metallo-β-lactamase
^aIsolates of Morganella spp., Proteus spp., Providencia spp. or Serratia spp. were excluded due to intrinsic resistance
^bTigecycline EUCAST breakpoints only apply to isolates of Citrobacter koseri and Escherichia coli
^cIsolates in this subset are carbapenemase-positive and MBL-positive

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us